MoonLake Immunotherapeutics (MLTX) Announces $150M Share, Warrant Offering; Stock Declines

MoonLake Immunotherapeutics (MLTX) announced on June 23, 2026, a proposed public offering of $150 million of its ordinary shares and warrants to purchase additional ordinary shares. The news prompted a decline in the company's stock price, as investors reacted to the potential for dilution from the new issuance. The offering structure includes ordinary shares and accompanying warrants, with each warrant exercisable for one ordinary share. MoonLake also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares and warrants. Proceeds are earmarked for general corporate purposes, including clinical development and working capital.